AstraZeneca plans to invest 190 million yuan ($26.7 million) in China to build a new production line to produce a diabetes drug approved for sale in the local market in 2022.
This is reported by the Shanghai "Yicai Global" business platform.
AstraZeneca plans to invest 190 million yuan ($26.7 million) in China to build a new production line to produce a diabetes drug approved for sale in the local market in 2022.
This is reported by the Shanghai "Yicai Global" business platform.